Dr. Wang will highlight how AI is transforming drug discovery. Artificial Intelligence for drug discovery (AIDD), the evolution of computer-aided drug design, is now involved in all stages of development pipeline from target identification to market, slashing timelines and costs. Preclinical phases can be halved, phase I accelerated. Pharma giants are partnering with AI companies, applying it in all key therapeutic areas. AI shines in small molecule drugs, but its reach is expanding to large molecule drugs like antibodies and ADC. In recent years, Dr. Wang’s lab has pioneered the application of AI/ML methodologies to expedite early drug development, achieving successes with multiple targets. He has also championed the use of AI/ML to fine-tune reaction conditions for visible-light photocatalysis in heterocycle synthesis; to enhance packaging capacity in therapeutic gene delivery.
Learning Objectives:
Upon completion, participants will be able to understand the basic principles of Artificial Intelligence for Drug Discovery (AIDD) and how it represents an evolution from traditional computer-aided drug design.
Upon completion, participants will be able to discuss the key stages of small molecule drug discovery pipeline and how AI is impacting each stage, including target identification, lead generation, optimization, and preclinical & clinical trials.
Upon completion, participants will be able to demonstrate an understanding of how AI is expanding its reach to large molecule drugs such as antibodies and ADCs.
.jpg "Mitra Mosharraf, M Pharm, PhD, MBA photo")